相关临床试验
9
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
进行中（未招募）
2
22.2%
Enrolling By Invitation
2
22.2%
招募中
5
55.6%
暂无批准数据
- Eli Lilly has signed a strategic research and licensing agreement worth up to $1.1 billion with Dresden-based Seamless Therapeutics to develop gene therapies for genetically caused hearing loss. - The collaboration leverages Seamless's proprietary recombinase platform, which enables precise DNA insertions and modifications without relying on cellular DNA repair mechanisms, differentiating it from CRISPR/Cas technology. - The deal includes guaranteed upfront payments and committed R&D funding, with Lilly receiving exclusive licensing rights to advance candidates through preclinical and clinical development. - This partnership represents a significant validation of Seamless's gene editing platform and positions the company for potential additional collaborations while advancing their own internal programs.
- Upstream Bio has appointed Stacy Price as Chief Technology Officer, bringing over 25 years of biotechnology experience to oversee technical operations and product development for verekitug. - Price will focus on chemistry, manufacturing, and controls (CMC) processes and drug delivery as Upstream Bio prepares to initiate a third clinical program for verekitug, their monoclonal antibody targeting inflammatory respiratory diseases. - The appointment comes at a pivotal time for Upstream Bio as they advance verekitug in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps, with plans to expand into chronic obstructive pulmonary disease.
• Eli Lilly has agreed to acquire hearing loss gene therapy developer Akouos for up to $610 million, with an initial payment of $487 million and potential milestone-based payments of up to $123 million. • Akouos's lead candidate AK-OTOF, targeting otoferlin gene mutations in sensorineural hearing loss, has received FDA approval for clinical testing and could potentially benefit 200,000 patients worldwide. • The acquisition strengthens Lilly's gene therapy portfolio and expands its presence in genetic medicine, following its previous $1 billion acquisition of Prevail Therapeutics in 2020.
